Quick Answer
KalVista Pharmaceuticals, Inc. reported Net Income Loss of -$183.44 million for the year ending 2025.
- KalVista Pharmaceuticals, Inc. showed a decrease of -44.9% in Net Income Loss from 2024 to 2025.
- This data is from KalVista Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on July 10, 2025.
- XBRL data for this metric is available from 2013 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: -$1.95 million | Q1 2016: -$6.61 million | Q2 2016: -$4.87 million | Q2 2016: -$7.35 million | Q3 2016: -$3.44 million | Q3 2016: -$2.39 million | Q4 2016: -$3.30 million | Q1 2017: -$7.64 million | Q2 2017: -$4.20 million | Q3 2017: -$4.93 million | Q4 2017: -$4.99 million | Q1 2018: -$5.23 million | Q2 2018: -$657.0 thousand | Q3 2018: -$5.03 million | Q4 2018: -$3.30 million | Q1 2019: -$3.96 million | Q2 2019: -$8.53 million | Q3 2019: -$7.34 million | Q4 2019: -$5.90 million | Q1 2020: -$9.29 million | Q2 2020: -$6.59 million | Q3 2020: -$10.81 million | Q4 2020: -$10.43 million | Q1 2021: -$10.05 million | Q3 2021: -$16.11 million | Q4 2021: -$19.65 million | Q1 2022: -$22.47 million | Q3 2022: -$23.04 million | Q4 2022: -$22.26 million | Q1 2023: -$21.30 million | Q3 2023: -$25.32 million | Q4 2023: -$27.65 million | Q1 2024: -$29.03 million | Q1 2024: -$43.11 million | Q2 2024: -$40.34 million | Q3 2024: -$40.44 million | Q3 2024: -$39.08 million | Q4 2024: -$42.27 million | Q1 2025: -$48.51 million | Q1 2025: -$51.84 million | Q2 2025: -$57.60 million | Q3 2025: -$60.10 million | Q3 2025: -$49.48 million.
- Over the full 14 years of available data (2013 to 2025), KalVista Pharmaceuticals, Inc.'s Net Income Loss has declined by 3,130.8%.
- Historical annual values: Fiscal year 2025: -$183.44 million | Fiscal year 2024: -$126.64 million | Fiscal year 2023: -$92.91 million | Fiscal year 2022: -$82.34 million | Fiscal year 2021: -$46.24 million | Fiscal year 2020: -$29.12 million | Fiscal year 2019: -$20.82 million | Fiscal year 2018: -$15.81 million | Fiscal year 2017: -$18.60 million | Fiscal year 2016: -$11.44 million | Fiscal year 2015: -$24.85 million | Fiscal year 2015: -$7.23 million | Fiscal year 2014: -$13.36 million | Fiscal year 2013: -$5.68 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: